CDK4/6 inhibition in pancreatic cancer: lessons learned as the therapeutic landscape evolves

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, with only incremental survival gains despite the adoption of multi-agent chemotherapy regimens. Although combination cytotoxic therapy such as FOLFIRINOX or gemcitabine plus nab-paclitaxel has become standard in the frontline setting, outcomes for patients with advanced disease remain poor, and effective later-line options are limited (1,2). Moreover, with rare exceptions, these cancers are not amenable to treatments with nonchemotherapy medical management, such as biomarker targeted therapies or immunotherapies. These realities continue to motivate the exploration of biologically rational strategies that move beyond conventional cytotoxic intensification. Among these, targeting cell-cycle regulatory pathways has emerged as an area of active investigation.

In this context, Alese and colleagues report a phase I study evaluating the combination of palbociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, with platinum chemotherapy in patients with advanced solid tumors, with an expansion cohort enriched for pancreaticobiliary cancers (3). The study was grounded in a compelling biologic rationale. Loss of CDKN2A and broader dysregulation of the CDK4/6-RB cell-cycle axis are observed in the vast majority of PDAC tumors, positioning cell-cycle control as an attractive therapeutic target (4,5). Moreover, combining CDK4/6 inhibition with DNA-damaging agents such as platinum compounds raises the possibility of impairing cell-cycle recovery following genotoxic stress.

The investigators employed a familiar Bayesian dose-escalation strategy to define recommended phase II doses for palbociclib in combination with either cisplatin or carboplatin. From a safety and feasibility standpoint, the study met its primary objectives. Toxicities were predictable and largely consistent with the known myelosuppressive effects of both palbociclib and platinum chemotherapy. Importantly, the regimen proved tolerable even in a heavily pretreated population, establishing that CDK4/6 inhibition can be safely combined with platinum agents in this setting (3).

The study enrolled an atypically diverse cohort, with 32% of participants identifying as Black, substantially exceeding the 8.2% representation reported across U.S. pancreatic cancer clinical trials that disclose race (6). This is particularly noteworthy given the persistent underrepresentation of Black patients in pancreatic cancer clinical trials. In a nationwide analysis, only 0.19% of Black patients with PDAC participated in clinical trials compared with 0.49% of White patients, a disparity that has remained largely unchanged over time despite overall increases in enrollment (7). Black Americans also experience both higher incidence and worse survival from PDAC; however, population-based analyses suggest that differences in receipt of treatment explain only about one-fourth of the observed survival disparity, indicating that additional structural and disease-presentation factors likely contribute (8). In this context, the robust minority representation achieved in this study enhances the generalizability of its findings and provides important safety and feasibility data for CDK4/6 inhibition in a historically understudied population.

Efficacy outcomes in this trial, primarily considering feasibility, were nonetheless modest. In the pancreatic adenocarcinoma expansion cohort, no objective responses were observed among 28 patients, and median progression-free survival was approximately two months. Although disease stabilization was achieved in a subset of patients, the overall signal was limited. Notably, nine patients (32%) experienced disease progression before the first scheduled restaging scan, suggesting either aggressive disease biology, rapid therapeutic failure, or rebound phenomenon following discontinuation of prior therapy. These findings align with prior negative data from the TAPUR study, which demonstrated no clinical activity with palbociclib monotherapy in patients with CDKN2A-altered pancreatic and biliary cancers (9).

Several considerations are critical to interpreting these findings. First, the study population was heavily pretreated, with most patients having received a median of three prior lines of therapy, and some as many as seven. The majority of patients with metastatic PDAC do not receive third-line therapy; those who do represent a survival-selected subset with favorable tumor biology, sustained performance status, and access to specialized care. While such patients are clinically selected by these favorable features, they are also biologically enriched for treatment-resistant disease. In this context, the absence of meaningful activity underscores the limited therapeutic signal observed with this approach in advanced PDAC.

Second, endpoint selection deserves careful scrutiny. Objective response rate served as the primary endpoint, yet tumor shrinkage may be an imperfect measure of activity for agents that primarily exert cytostatic rather than cytotoxic effects, in which benefit may occur without radiographic response (10). While disease control can provide a complementary signal, it remains an imperfect surrogate, particularly in rapidly progressive malignancies such as PDAC. These challenges highlight the importance of aligning trial endpoints with the underlying biology of the therapeutic strategy being tested.

Third, the choice of chemotherapy backbone has important implications for clinical translation. Cisplatin and carboplatin are not routinely used in PDAC outside of select molecular contexts, most notably tumors with homologous recombination deficiency (11). As a result, the findings from this study cannot be readily extrapolated to contemporary frontline regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel (1,2). Although the use of a nonstandard backbone is acceptable in early-phase studies designed to probe biologic hypotheses, it requires careful reconsideration when approaching feasibility and relevance in subsequent phase II development.

The biomarker-agnostic design of the study represents both a strength and a limitation. On one hand, it allowed for an unbiased assessment of whether CDK4/6 pathway inhibition might have broad relevance in PDAC. On the other hand, the absence of a robust efficacy signal underscores the likelihood that future efforts in this space would require biomarker-driven patient selection rather than unselected enrollment. Indeed, the presence of CDKN2A alterations alone may not constitute a sufficient predictive biomarker for CDK4/6 inhibitor sensitivity; functional dependence on the CDK4/6-RB axis, as reflected by intact RB1 expression, may be a necessary co-requisite to identify patients most likely to derive benefit. The exploratory association between BRCA mutations and improved progression-free survival, while biologically plausible, was based on very small numbers and is best interpreted as hypothesis-generating, likely reflective of platinum sensitivity rather than definitive synergy with CDK4/6 inhibition (3,11).

These findings must also be viewed in the context of a rapidly changing PDAC therapeutic landscape. Direct targeting of KRAS, long considered undruggable, has begun to yield clinical proof of concept in pancreatic cancer. In molecularly selected KRAS G12C-mutant PDAC cohorts, early-phase studies of KRAS G12C inhibitors have demonstrated objective responses and disease control (12,13). Parallel efforts to target KRAS G12D, the most prevalent KRAS alteration in PDAC, are advancing into clinical testing, with early signals of antitumor activity reported in phase 1 data sets that include PDAC-enriched cohorts (14). In addition, methylthioadenosine phosphorylase (MTAP) loss, which frequently co-occurs with CDKN2A deletion in PDAC, creates a synthetic lethal dependency on PRMT5 and has emerged as a promising vulnerability, with MTA-cooperative PRMT5 inhibition demonstrating preliminary clinical activity across MTAP-deleted solid tumors, including pancreatic cancer (15,16). Cell-surface targets such as Claudin-18.2 are also being evaluated in PDAC, including in combination with standard chemotherapy backbones (17). As these programs move earlier in the disease course, the bar for advancing additional strategies has risen. Any future role for CDK4/6 inhibition in PDAC would need to be clearly articulated relative to these emerging anchors, potentially as a rational partner therapy or resistance-modulating strategy rather than as a standalone backbone.

Taken together, the results reported by Alese and colleagues do not support the pursuit of a conventional phase II program testing palbociclib plus platinum chemotherapy in unselected, refractory PDAC. However, this does not preclude a future role for CDK4/6 inhibition in PDAC; rather, it underscores the need for a more refined investigative approach. The study makes an important contribution by defining the boundaries within which cell-cycle targeting is unlikely to succeed in this disease. In doing so, it reinforces a broader lesson for PDAC drug development: target validity alone is insufficient. Timing, patient selection, chemotherapy backbone, and endpoint alignment are equally critical determinants of clinical success. Future studies should evaluate CDK4/6 inhibitors in earlier lines of therapy, in combination with standard PDAC chemotherapy regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel, and in biomarker-selected populations enriched for CDK4/6 pathway dependence, such as those with confirmed CDKN2A loss and intact RB1 expression.

In an era increasingly defined by biomarker-driven therapy, studies such as this serve a valuable role by clarifying not only where progress can be made, but also where alternative strategies are needed. The challenge ahead lies in integrating foundational biologic insights with evolving molecular anchors to design trials that are both mechanistically sound and clinically meaningful for patients with pancreatic cancer.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Pancreatic Cancer. The article has undergone external peer review.

Peer Review File: Available at https://apc.amegroups.com/article/view/10.21037/apc-26-0011/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://apc.amegroups.com/article/view/10.21037/apc-26-0011/coif). B.S. discloses honorarium for lecturing at a state society meeting (Idaho Society Clinical Oncology) and clinical evaluation committee work for Boehringer Ingelheim. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. [Crossref] [PubMed]
2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. [Crossref] [PubMed]
3. Alese OB, Harvey RD, Wu C, et al. Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer. Oncologist 2025;30:oyaf284. [Crossref] [PubMed]
4. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6. [Crossref] [PubMed]
5. Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6:6744. [Crossref] [PubMed]
6. Herremans KM, Riner AN, Winn RA, et al. Diversity and Inclusion in Pancreatic Cancer Clinical Trials. Gastroenterology 2021;161:1741-1746.e3. [Crossref] [PubMed]
7. Hue JJ, Katayama ES, Markt SC, et al. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Surgery 2022;172:257-64. [Crossref] [PubMed]
8. Singal V, Singal AK, Kuo YF. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. J Cancer Res Clin Oncol 2012;138:715-22. [Crossref] [PubMed]
9. Al Baghdadi T, Halabi S, Garrett-Mayer E, et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol 2019;3:1-8. [Crossref] [PubMed]
10. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72. [Crossref] [PubMed]
11. O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol 2020;38:1378-88. [Crossref] [PubMed]
12. Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 2023;388:33-43. [Crossref] [PubMed]
13. Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17. [Crossref] [PubMed]
14. Spira AI, Papadopoulos KP, Kim DW, et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J Clin Oncol 2025;43:724.
15. Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016;351:1214-8. [Crossref] [PubMed]
16. Belmontes B, Slemmons KK, Su C, et al. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. Cancer Discov 2025;15:139-61. [Crossref] [PubMed]
17. Park W, O'Reilly EM, Furuse J, et al. Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. J Clin Oncol 2023;41:TPS782.